Obudanersen is an antisense oligonucleotide targeted to ubiquitin protein ligase E3A-antisense transcript (UBE3A-ATS). It is used for the study of Angelman syndrome.

Obudanersen sodium is an antisense oligonucleotide targeted to ubiquitin protein ligase E3A-antisense transcript (UBE3A-ATS). It is used for the study of Angelman syndrome.

Obeversen sodium is an antisense oligonucleotide that inhibits the synthesis of Diacylglycerol acyltransferase 2 (DGAT-2). Obeversen sodium can be used in the research of nonalcoholic fatty liver disease.

S 3578 (sulfate) is a broad-spectrum antibacterial agent, particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) (MIC = 0.78-3.13 μg/mL) and Pseudomonas aeruginosa (MIC = 1.56-6.25 μg/mL). S 3578 (sulfate) can be used in the research of infectious conditions.

SPAA-52 (ammonium) is a low molecular weight protein tyrosine phosphatase (LMW-PTP) inhibitor (IC50 = 4 nM; IC50 = 1.2 nM). SPAA-52 (ammonium) can be used in the research of diabetes mellitus.

FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.

OZO-H is a GST inhibitor. OZO-H is an OZO derivative with potent anti-cancer effects. OZO-H releases JNK1 from GST-JNK1 complex. OZO-H induces JNK1 phosphorylation and activates c-Jun in cancer cells.

OZO-Cl is an OZO derivative. OZO-Cl has anti-cancer activity. OZO-Cl significantly decreases the intracellular glutathion S-transferase Pi (GST) activity. OZO-Cl exhibits cytotoxicity to cancer cell lines, with IC50s of 150 and 120 μmol/L in Panc-1 and K562 cells respectively.

BO 1341 is a PBPs inhibitor and an antipseudomonal semisynthetic cephalosporin. BO 1341 exhibits antibacterial activity against most Gram-negative bacteria, such as Pseudomonas aeruginosa (MIC90: 1.56 μg/mL), Pseudomonas maltophilia (MIC50: 1.56 μg/mL), and Acinetobacter calcoaceticus (MIC90: 3.13 μg/mL) . BO 1341 can be used in the research of infectious diseases.

DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins.

ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa.

Nucresiran is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nucresiran sodium is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nivudirsen is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

Nivudirsen sodium is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

E3 Ligase Ligand-linker Conjugate 179 is an E3 ubiquitinase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 179 can be used to synthesize JV8.

Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.

(S,R,S)-AHPC-amide-PEG5-C2-azide (VH032-CO-(CH2)2-(O-CH2-CH2)5-azide) is a PROTAC linker that can be used to design PROTACs.

FBnG-amino-PEG3-C2-azido is a tag-linker conjugate that incorporates a degradation tag FBnG and a glycol linker (Amino-PEG3-C2-Azido). FBnG-amino-PEG3-C2-azido can be used for synthesis of GPX4-AUTAC

Duazomycin (Duazomycin A) sodium is a glutamine antagonist. Duazomycin sodium can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) in experimental allergic encephalomyelitis (EAE) without increasing toxicity.

Movronersen is an antisense oligonucleotide targeted to α-synuclein.

Movronersen sodium is an antisense oligonucleotide targeted to α-synuclein.

Mivelsiran is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.

Mivelsiran sodium is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.

Lufepirsen is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.

Lufepirsen sodium is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.

Lixadesiran is a siRNA in STP705. It targets to COX-2. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Lixadesiran sodium is a siRNA in STP705. It targets to COX-2. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Litenimod is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.